4. Issues of Ethnopharmacology in HIV Management
Summary
There are 2 distinct types of HIV: HIV-1 and HIV-2. Both are transmitted in the same ways and are characterized by the same clinical manifestations. However, worldwide, HIV-1 is by far the more common of the 2 types, whereas cases of HIV-2 infection are rare outside West Africa. Although no more than a few hundred cases of HIV-2 infection have been identified in the United States, the CDC has cautioned that the number of US cases is likely underestimated, primarily because of issues concerning the sensitivity of the diagnostic assays used in some settings.
HIV-1 infection is further categorized into 4 groups: M, which is the major group; O, which is a much less common group; and 2 newer groups, N and P. Because cases of Group M infection are so numerous and geographically dispersed, this group is further classified into subtypes (clades): A, B, C, D, F, G, H, J, K, and circulating recombinant forms. Some studies have indicated that some HIV subtypes are associated with more rapid disease progression and with differences in transmissibility.
Most currently marketed antiretrovirals were developed for use against HIV-1 clade B infections, but they appear to be equally effective against infections with viruses from other clades. However, patients infected with viruses from some clades may be more likely to develop resistance to particular antiretrovirals, and the types of resistance-associated mutations may vary. Not all of these agents have shown equal efficacy in treating HIV-2 infections, which typically are resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs), which should not be used in patients with HIV-2 infection.